ATE206463T1 - Virale vektoren für die gentherapie - Google Patents

Virale vektoren für die gentherapie

Info

Publication number
ATE206463T1
ATE206463T1 AT96926455T AT96926455T ATE206463T1 AT E206463 T1 ATE206463 T1 AT E206463T1 AT 96926455 T AT96926455 T AT 96926455T AT 96926455 T AT96926455 T AT 96926455T AT E206463 T1 ATE206463 T1 AT E206463T1
Authority
AT
Austria
Prior art keywords
viral
vector
contg
gene therapy
viral vectors
Prior art date
Application number
AT96926455T
Other languages
English (en)
Inventor
Majid Mehtali
Monika Lusky
Karola Rittner
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9508946A external-priority patent/FR2737221B1/fr
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE206463T1 publication Critical patent/ATE206463T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT96926455T 1995-07-24 1996-07-24 Virale vektoren für die gentherapie ATE206463T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9508946A FR2737221B1 (fr) 1995-07-24 1995-07-24 Nouveaux vecteurs viraux pour la therapie genique
FR9604413A FR2737222B1 (fr) 1995-07-24 1996-04-09 Nouveaux vecteurs viraux et lignee pour la therapie genique
PCT/FR1996/001165 WO1997004119A1 (fr) 1995-07-24 1996-07-24 Vecteurs viraux et lignee pour la therapie genique

Publications (1)

Publication Number Publication Date
ATE206463T1 true ATE206463T1 (de) 2001-10-15

Family

ID=26232115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96926455T ATE206463T1 (de) 1995-07-24 1996-07-24 Virale vektoren für die gentherapie

Country Status (12)

Country Link
US (2) US6204060B1 (de)
EP (2) EP0784693B1 (de)
JP (2) JPH10506542A (de)
AT (1) ATE206463T1 (de)
AU (1) AU712951B2 (de)
CA (1) CA2200696A1 (de)
DE (1) DE69615650T2 (de)
DK (1) DK0784693T3 (de)
ES (1) ES2164260T3 (de)
FR (1) FR2737222B1 (de)
PT (1) PT784693E (de)
WO (1) WO1997004119A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JP4051416B2 (ja) * 1995-06-15 2008-02-27 クルーセル ホランド ベスローテン フェンノートシャップ 遺伝子治療に使用されるヒト組換えアデノウイルス用のパッケージングシステム
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
FR2737222B1 (fr) * 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
FR2763959A1 (fr) * 1997-06-02 1998-12-04 Transgene Sa Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
IL135776A0 (en) * 1997-10-24 2001-05-20 Life Technologies Inc Recombinational cloning using nucleic acids having recombination sites
US7060479B2 (en) * 1999-12-08 2006-06-13 Serono Genetics Institute, S.A. Full-length human cDNAs encoding potentially secreted proteins
US7223727B2 (en) * 1998-04-09 2007-05-29 Serono Genetics Institute S.A. GSSP4 polynucleotides and polypeptides and uses thereof
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JP2002520069A (ja) * 1998-07-14 2002-07-09 メルク・アンド・カンパニー・インコーポレーテッド アデノウイルスに基づくプロモーターアッセイ
DE19907099A1 (de) * 1999-02-19 2000-09-07 Theragene Biomedical Lab Gmbh Hormon-Hormonrezeptorkomplexe und Nukleinsäurekonstrukte und ihre Verwendung in der Gentherapie
US7226786B2 (en) 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
CA2382165A1 (en) * 1999-12-08 2001-06-14 Genset S.A. Full-length human cdnas encoding potentially secreted proteins
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20050100888A1 (en) * 2002-03-02 2005-05-12 Imperial College Innovations Limited Methods based on hormone dependency of primary cancer cells
GB0204967D0 (en) * 2002-03-02 2002-04-17 Imp College Innovations Ltd Methods
AU2003253992A1 (en) * 2002-07-18 2004-02-09 Robert P. Bennett Viral vectors containing recombination sites
AU2003268145A1 (en) * 2002-08-22 2004-03-11 Merck And Co., Inc. Methods for propagating adenovirus and virus produced thereby
US7887539B2 (en) 2003-01-24 2011-02-15 Depuy Spine, Inc. Spinal rod approximators
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
CA2532783C (en) 2003-07-21 2013-09-17 Transgene S.A. Polypeptide having an improved cytosine deaminase activity
WO2005054438A2 (en) 2003-12-01 2005-06-16 Invitrogen Corporation Nucleic acid molecules containing recombination sites and methods of using the same
US7951175B2 (en) 2005-03-04 2011-05-31 Depuy Spine, Inc. Instruments and methods for manipulating a vertebra
US7951172B2 (en) 2005-03-04 2011-05-31 Depuy Spine Sarl Constrained motion bone screw assembly
US7722651B2 (en) 2005-10-21 2010-05-25 Depuy Spine, Inc. Adjustable bone screw assembly
GB0521582D0 (en) 2005-10-22 2005-11-30 Depuy Int Ltd An implant for supporting a spinal column
CA2627485C (en) 2005-10-28 2017-02-21 Katsuyuki Mitomo Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus or dna virus spike protein
GB0600662D0 (en) 2006-01-13 2006-02-22 Depuy Int Ltd Spinal support rod kit
US8348952B2 (en) 2006-01-26 2013-01-08 Depuy International Ltd. System and method for cooling a spinal correction device comprising a shape memory material for corrective spinal surgery
GB0720762D0 (en) * 2007-10-24 2007-12-05 Depuy Spine Sorl Assembly for orthopaedic surgery
DK2222697T3 (da) 2007-11-01 2013-03-11 Perseid Therapeutics Llc Immunsuppressive polypeptider og nukleinsyrer
US8608746B2 (en) 2008-03-10 2013-12-17 DePuy Synthes Products, LLC Derotation instrument with reduction functionality
US8709015B2 (en) 2008-03-10 2014-04-29 DePuy Synthes Products, LLC Bilateral vertebral body derotation system
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
US10973556B2 (en) 2008-06-17 2021-04-13 DePuy Synthes Products, Inc. Adjustable implant assembly
CN102281892A (zh) 2009-01-13 2011-12-14 特朗斯吉有限公司 酿酒酵母线粒体核酸级分用于免疫刺激的用途
WO2011083881A1 (ja) 2010-01-08 2011-07-14 国立大学法人京都大学 タウオパチー治療用ワクチン
EP2912069B1 (de) 2012-10-23 2019-07-31 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
WO2018093932A2 (en) 2016-11-16 2018-05-24 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
CA3061206A1 (en) 2017-04-22 2018-10-25 Immunomic Therapeutics, Inc. Improved lamp constructs
KR20240027895A (ko) 2017-05-02 2024-03-04 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
WO2020026968A1 (ja) 2018-07-30 2020-02-06 株式会社遺伝子治療研究所 Ａａｖベクターによる遺伝子発現を増強する方法
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
CA3153850A1 (en) 2019-10-18 2021-04-22 Teri Heiland Improved lamp constructs comprising cancer antigens
CN114980920A (zh) 2019-11-18 2022-08-30 詹森生物科技公司 基于突变体calr和jak2的疫苗及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
EP4135757A1 (de) 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma- und steap1-impfstoffe und ihre verwendungen
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
DK0667912T3 (da) * 1993-07-13 2008-11-10 Centelion Defekte adenovirusvektorer og anvendelse heraf i genterapi
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
FR2735789B1 (fr) * 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
FR2737222B1 (fr) * 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique

Also Published As

Publication number Publication date
AU6663096A (en) 1997-02-18
PT784693E (pt) 2002-03-28
EP1096018A1 (de) 2001-05-02
AU712951B2 (en) 1999-11-18
EP0784693A1 (de) 1997-07-23
JPH10506542A (ja) 1998-06-30
ES2164260T3 (es) 2002-02-16
JP2008017849A (ja) 2008-01-31
WO1997004119A1 (fr) 1997-02-06
DK0784693T3 (da) 2002-01-21
US20030203488A1 (en) 2003-10-30
FR2737222B1 (fr) 1997-10-17
US6204060B1 (en) 2001-03-20
DE69615650T2 (de) 2002-07-11
CA2200696A1 (fr) 1997-02-06
EP0784693B1 (de) 2001-10-04
FR2737222A1 (fr) 1997-01-31
DE69615650D1 (de) 2001-11-08

Similar Documents

Publication Publication Date Title
DE69615650D1 (de) Virale vektoren für die gentherapie
JPS57134500A (en) Plasmid pcg1
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
HK1018078A1 (en) Recombinant sendai virus
DE69435187D1 (de) Erhöhte expression in pflanzen durch verwendung von nicht-translierter leader-sequenz
SE8007998L (sv) Forfarande for framstellning av interferon
ES2013324A6 (es) Un metodo mejorado para producir una proteina heterologa.
HK1018287A1 (en) (-)-strand rna virus vector having autonomously replicating activity
CA2321964A1 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus
GB8718779D0 (en) Dna sequence & expression vector
DK0632129T3 (da) Rekombinante foamy-virusvektorer til medicinsk og diagnostisk anvendelse, og fremgangsmåder til at præparere rekombinante foamy-virusvektorer
DE3478699D1 (en) Method for producing interferons
ATE192499T1 (de) Herstellung rekombinanter proteine unter verwendung von herpes-virus-promotoren und vp16- transaktivatoren
DK0988391T3 (da) Rekombinante adenovirusvektorer der omfatter en splejsningssekvens
IL92264A0 (en) Process for the expression of recombinant genes
IL130876A0 (en) Eukaryotic gene expression cassette and uses thereof
EP0242220A3 (en) Gene expression system
ES2003462A6 (es) Un metodo de obtencion de un alto nivel de expresion de una proteina.
WO1997014808A3 (en) Herpesvirus vectors and their uses
GB2331989B (en) Retroviral vectors
IL92265A0 (en) Expression enhancer and employment thereof to increase the yield in the expression of recombinant genes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee